The SomaScan® Assay enables discovery of blood-based biomarkers in neurodegenerative diseases

image of the white paper

Blood-based biomarkers show promise as a minimally invasive, cost-effective option for the detection, classification, and monitoring of neurologic diseases.1-3

References: 1. Polaskova V, Kapur A, Khan A, Molloy MP, Baker MS. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis. 2010;31(3):471-482. doi:10.1002/elps.200900286. 2. Tanaka T, Lavery R, Varma V, et al. Plasma proteomic signatures predict dementia and cognitive impairment. Alzheimers Dement (N Y). 2020;6(1):e12018. doi:10.1002/trc2.12018. 3. Shi L, Buchanan CR, Cox SR, et al. Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals. Alzheimers Dement (Amst). 2021;13(1):e12240. doi:10.1002/dad2.12240.


More White Papers

White paperCOVID-19 and the SomaScan® Platform

Learn more

White paperAssessing pre-analytical variation for more accurate proteomic data

Learn more

White paperDetection of low-abundance serum proteins associated with Prediabetes for predictive and prognostic purposes

Learn more

Explore external publications in our interactive viewer